Clinical case series: Use of recombinant human collagen matrix for the management of chronic wounds of the foot
no. EP458
Aim: To present two clinical cases of patients with chronic neuropathic wounds of the foot, which were treated using a single application of human recombinant type I collagen produced in plants. Method: Two patients were treated in the outpatient department of Hospital of Lithuanian University of Health Sciences Kaunas Clinics. First case: 20 year old female with 2x1.5cm chronic wound of the left foot present for 2 months, second case: 17 year old male with a chronic wound of the right foot 0.3x0.4cm, present for 10 months. Both patients had neuropathic chronic wounds of the sole of the foot due to lack of sensation in the limbs caused by myelomeningocele. Both wounds did not respond to debridement and treatment with hydrocolloid and foam dressings. Wounds were photographed and preliminary surgical debridement was performed followed by single application of recombinant human collagen matrix and secondary hydrocolloid dressing. Patients were followed up weekly for 4 weeks. Results / Discussion: Significant wound closure was noticed in both cases. In first case, full wound epithelization was seen after 2 weeks, with full wound closure after 1 month. In second case, significant wound reduction in depth and diameter (>80%) was seen within 2 weeks. No adverse effects were seen. Conclusion: Single use of recombinant human collagen matrix filler for chronic foot wounds may promote wound closure with minimal adverse events. Vergenix™ Flow Gel